You are here


Company Information
310 E 67th St Ste 1-12
New York, NY 10065-6275
United States


DUNS: 965188084

# of Employees: 11

Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No

Award Charts

Award Listing

  1. Development of an LXR agonist as first in class therapy for treatment of metastatic melanoma

    Amount: $1,639,260.00

    Abstract Metastatic melanoma remains incurable for the majority of patients Of the patients diagnosed with Stage IIB IV melanoma annually do not respond to existing treatments and for t ...

    SBIRPhase II2016Department of Health and Human Services National Institutes of Health
  2. A microRNA based prognostic service that predicts melanoma metastasis likelihood

    Amount: $199,654.00

    ABSTRACT Melanoma is a highly prevalent cancer that kills patients by metastasizing and destroying distal organs. To date, there are no effective molecular prognostic services available for stratifyin ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government